Non-Executive Director Appointment

RNS Number : 2271I
MaxCyte, Inc.
01 December 2022



MaxCyte Appoints Patrick J. Balthrop as Non-Executive Director




Rockville, MD, 1 December, 2022: MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announces the appointment of Patrick J. Balthrop, Sr. to the company's Board of Directors as non-executive director with immediate effect. Mr. Balthrop is also appointed as non-executive member of the Nominating and Corporate Governance Committee.


Mr. Balthrop has more than 35 years of experience in the healthcare sector, particularly in the life sciences segments of diagnostics, life science tools, and medical devices. He was CEO, President, and Director of  Luminex Corporation (NASDAQ: LMNX) for over 10 years, quadrupling the company's revenue in five years. Prior to this he was President of Fisher Healthcare (then Fisher Scientific). He held positions at Abbott Laboratories over a period of 20 years including head of Abbott Vascular and Corporate VP of Worldwide Operations for Abbott Diagnostics.


Mr. Balthrop currently serves as Chairman of the Board for both Agendia, Inc. and Discovery Life Sciences, and as Director of Pattern Biosciences. He has previously held board positions at publicly listed life science companies, including Oxford Immunotec Global (NASDAQ: OXFD), and Personalis, Inc. (NASDAQ: PSNL). Additionally, he serves as Executive Advisor to Water Street Healthcare Partners and is a Founding Principal of Apalachee Ventures.


Mr. Balthrop received an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University, and a B.S. in Biology from Spring Hill College.


"Patrick has an outstanding track-record of building, growing, and optimizing businesses in the life sciences sector, and we are delighted and honored to welcome him to our Board," said Doug Doerfler, President and CEO of MaxCyte. "We look forward to drawing on his invaluable experience and insight as we continue to advance the next-generation of cell therapy discovery, development and commercialization."


Grant of options

Upon appointment, Mr. Balthrop has been granted 100,000 options over common stock, $0.01 par, of the Company ("Options"). These Options vest over three (3) years, with initial vesting of 1/3rd of the total after twelve (12) months, and the remainder vesting monthly over the following twenty-four (24) months. The Options have an exercise price of $5.99, equal to the closing price of MaxCyte's stock on 30 November, 2022.


Additional Disclosures

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies.

Mr Patrick James Balthrop, Sr. (aged 66) holds or has held the following current and former directorships in the past five years:

Current Directorships

Former Directorships in the past five years

Agendia NV

Chromacode, Inc

Apalachee Ventures, LLC

Oxford Immunotec Global Limited

Discovery Life Sciences, LLC

Oyster City Brewing Company, LLC

Made by the Water, LLC

Personalis, Inc

Pattern Bioscience, Inc



Save as set out above, no further information regarding Patrick Balthrop is required to be disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies.




Details of the person discharging managerial responsibilities/person closely associated



Patrick Balthrop


Reason for the notification



Non-Executive Directors


Initial notification/Amendment

Initial notification


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



MaxCyte, Inc.





Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted


Description of the financial instrument, type of instrument

 Options over common stock , $0.01 par, of the Company


Identification Code



Nature of the transaction

Grant of Options


Price(s) and volume(s)

100,000 Options  at an exercise price of $5.99


Aggregated information

- Aggregated volume

- Price





Date of the transaction

30 November 2022


Place of the transaction

Nasdaq Stock Exchange



About MaxCyte

MaxCyte is a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® technology, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. Learn more at and follow us on Twitter and LinkedIn .



MaxCyte Contacts:


US IR Adviser

Gilmartin Group

David Deuchler, CFA

+1 415-937-5400


US Media Relations

Spectrum Seismic Collaborative

Valerie Enes

+1 408-497-8568


Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500


UK IR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
UK 100